Trial
NCT01386398
Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma
Phase IIIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators
—
Condition
Lymphoma
Intervention
bortezomib
Why stopped
Company withdrew interest
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-01-21